Aldeyra Therapeutics Director Richard Douglas Buys $129K of Stock
Richard Douglas, Director, bought 200,000 shares of Aldeyra Therapeutics, Inc. at $0.6445 a share, worth $129K in total on Nov 11, 2026. Shares held after the trade: 395,000 (+102.6%).
Aldeyra Therapeutics has requested that the FDA transfer the review jurisdiction of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2. In connection with this request, the company has withdrawn its previously agreed-upon Special Protocol Assessment (SPA) protocol, creating uncertainty and potential delays in the clinical development timeline for the candidate.
Aldeyra Therapeutics reported a net loss of $3.8 million for the third quarter of 2026, a significant reduction from the $7.7 million loss in the same period of 2025, primarily driven by lower research and development expenses. The company's cash position decreased to $41.0 million as of September 30, 2026, following the full repayment of its $15.0 million long-term debt during the year.
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.